Compugen Ltd. (CGEN, Financial), a clinical-stage therapeutic discovery and development company, recently experienced a significant stock fluctuation with a 5.17% drop in its share price, now trading at $1.38. The trading volume reached 205,290 shares, with a turnover rate of 0.23% and a price fluctuation amplitude of 8.28%.
According to the latest financial reports, Compugen posted a revenue of $17.13 million and a net profit of $1.28 million, resulting in an earnings per share of $0.01. The company's gross profit stood at $13.53 million, and it has a price-to-earnings ratio of 46.17. Among the three institutions rating the stock, all have given a "buy" recommendation, with no "hold" or "sell" ratings.
In the broader biotechnology sector, where Compugen operates, the overall growth was 0.65%. Notable stocks in the sector showing significant gains include Replimune Group, Inc., Exicure, Inc., and Rocket Pharmaceuticals Inc. C/Wts. Other active stocks with high turnover rates were Virpax Pharmaceuticals, Inc., Exicure, Inc., and Molecular Templates, Inc. Stocks with notable price fluctuations included Apollomics Inc. C/Wts, Ocean Biomedical Inc. C/Wts, and Virpax Pharmaceuticals, Inc.
Compugen focuses on discovering and developing cancer immunotherapy treatments using predictive computational discovery capabilities. Its immune-oncology pipeline includes four clinical-stage projects targeting immune checkpoints discovered through computation, such as COM701, COM902, and bapotulimab. The company also has early-stage projects targeting various immune resistance mechanisms, including bone marrow targets.
